Lercanidipine Accord (Lercanidipine Hydrochloride)

Lercanidipine is used to treat hypertension, a condition characterized by elevated arterial blood pressure.

• Essential hypertension: lowers systolic and diastolic pressure to reduce cardiovascular risk.
• Isolated systolic hypertension: provides arterial vasodilation to control high systolic readings.
• Secondary hypertension: assists in managing blood pressure when caused by other underlying conditions.
• Hypertension in elderly patients: offers once‑daily dosing to improve adherence.

• Lercanidipine selectively blocks L‑type calcium channels located on vascular smooth‑muscle cells. Inhibition of calcium influx prevents contraction of arterial smooth muscle, leading to vasodilation of peripheral arteries. The resulting decrease in systemic vascular resistance lowers both systolic and diastolic blood pressure without significant effect on heart rate, providing antihypertensive action. The drug’s high lipophilicity allows prolonged interaction with the channel, supporting once‑daily dosing and stable blood pressure control throughout the day.

Lercanidipine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache
• Flushing
• Peripheral edema

Serious or Rare Side Effects

• Severe hypotension
• Hepatic dysfunction
• Angioedema

When prescribing Lercanidipine, clinicians should consider several precautionary measures to ensure safe use.

• Blood pressure monitoring: regularly assess to avoid excessive hypotension.
• Hepatic impairment: use with caution and consider dose adjustment in patients with liver dysfunction.
• Elderly patients: start with the lowest effective dose due to increased sensitivity.
• Concomitant beta‑blockers: monitor for additive heart rate effects.
• Pregnancy and lactation: avoid unless benefits outweigh risks, as safety data are limited.
• Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Lercanidipine can interact with other medicines, influencing its antihypertensive effect or increasing adverse reaction risk.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma concentrations, increasing toxicity risk.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy by lowering drug levels.
• Grapefruit juice: can elevate Lercanidipine exposure, leading to enhanced hypotensive effect.

Moderate Interactions (Monitor Closely)

• Other antihypertensives (e.g., ACE inhibitors, diuretics): may cause additive blood pressure lowering.
• Simvastatin: increased risk of statin‑related muscle toxicity due to shared metabolism.